IP Library Granted Patent US 12,297,511
Granted Patent B2
US 12,297,511 · App. 16/816,031 · Granted May 13, 2025

Compositions and methods for detecting gastrointestinal pathogen nucleic acid

Inventor: Ejan Tyler (Encinitas, CA)
Assignee: Gen-Probe Prodesse, Inc.
C12Q1/689C12Q1/6844C12Q2537/143C12Q2600/16Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,511
App. No.
16/816,031
Granted
May 13, 2025
Kind
B2
Abstract

Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and combinations thereof, for detection of one or more gastrointestinal pathogens selected from Salmonella, Shigella, Campylobacter jejuni , and Campylobacter coli . Also disclosed are methods of specific nucleic acid amplification and detection, including multiplex assays, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Claims (15)

1. A multiplex method for determining the presence or absence of gastrointestinal pathogens comprising Campylobacter jejuni and Shigella in a sample, said method comprising:

(1) contacting a sample, said sample suspected of containing at least one of the gastrointestinal pathogens, with at least a first set of amplification oligomers for amplifying a first nucleic acid target region and a second set of amplification oligomers for amplifying a second nucleic acid target region, wherein

the first set of amplification oligomers comprises at least two C. jejuni -specific amplification oligomers for amplifying a target region of a C. jejuni target nucleic acid, wherein the at least two C. jejuni -specific amplification oligomers comprise first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:75 and SEQ ID NO:76; (ii) SEQ ID NO:51 and SEQ ID NO:52; (iii) SEQ ID NO: 55 and SEQ ID NO:56; (iv) SEQ ID NO:59 and SEQ ID NO:60; (v) SEQ ID NO:62 and SEQ ID NO:63; (vi) SEQ ID NO:66 and SEQ ID NO:67; or (vii) SEQ ID NO:71 and SEQ ID NO: 72; and

the second set of amplification oligomers comprises at least two Shigella -specific amplification oligomers for amplifying a target region of a Shigella target nucleic acid, wherein the at least two Shigella -specific amplification oligomers comprise first and second oligomers respectively comprising target-hybridizing sequences consisting of SEQ ID NO:45 and SEQ ID NO: 46;

(2) performing an in vitro nucleic acid amplification reaction, wherein any target nucleic acid, if present in said sample, is used as a template for generating one or more amplification products corresponding to the first and/or second target regions; and

(3) determining the sequences of the one or more amplification products, or detecting the presence or absence of the one or more amplification products using a first detection probe specific for the first target region and a second detection probe specific for the second target region,

thereby determining the presence or absence of C. jejuni and Shigella in said sample.

2. The method of claim 1 , where the amplification reaction is a polymerase chain reaction (PCR).

3. The method of claim 1 , wherein step (3) comprises use of the first and second detection probes.

4. The method of claim 3 , wherein the amplification reaction is a real-time polymerase chain reaction (RT-PCR).

5. The method of claim 1 , wherein each of the first and second detection probes comprises a fluorescent dye compound.

6. The method of claim 5 , wherein each of the first and second detection probes further comprises a non-fluorescent quenching dye compound.

7. The method of claim 1 , further comprising purifying the target nucleic acid from other sample components before step (1).

8. The method of claim 7 , wherein purifying the target nucleic acid comprises selectively separating the target nucleic acid from the other sample components using one or more target capture oligonucleotides each comprising a target hybridizing sequence joined at its 3′ end to a tail sequence.

9. The method of claim 8 , wherein the target hybridizing sequence of the one or more target capture oligonucleotides comprises a randomized or non-randomized poly-GU, poly-GT, or poly U sequence.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 054089/0804 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; GEN-PROBE PRODESSE, INC.
Reel/Frame 075504/0575 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2024
From: TYLER, EJAN
To: GEN-PROBE PRODESSE, INC.
Reel/Frame 066860/0666 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
Continuity (3)
Continuation 14650512
Provisional Application 61734873 · Dec 7, 2012
Related Publication 20200291460A1 · Sep 17, 2020
References Cited (37)
US 7892772B2 · Rohde · 2011 [cited by examiner]
US 10626467B2 · Tyler · 2020 [cited by applicant]
US 20040029129A1 · Wang · 2004 [cited by examiner]
US 20060177824A1 · Procop · 2006 [cited by applicant]
US 20070259337A1 · Hully · 2007 [cited by examiner]
US 20100035239A1 · Sampath et al. · 2010 [cited by applicant]
US 20150322495A1 · Tyler · 2015 [cited by applicant]
WO 2011097420A2 · 2011 [cited by applicant]
Cunningham et al. Three-hour molecular detection of [cited by examiner]
Wiemer et al. Real-time multiplex PCR for simultaneous detection of [cited by examiner]
Al Rashid et al. Identification of [cited by examiner]
Shen et al. MPprimer: a program for relaible multiplex PCR primer design. BMC Bioinformatics, vol. 11:143, p. 1-7, (2010). [cited by examiner]
AIPO Notice of Acceptance, Australian Patent Application No. 2013205090, Jul. 18, 2016. [cited by applicant]
AIPO Patent Examination Report No. 1, Australian Patent Application No. 2013205090, Jan. 6, 2016. [cited by applicant]
AIPO, Examination Report No. 1, Australian Patent Application No. 2016247158, Feb. 19, 2018. [cited by applicant]
AIPO, Notice of Acceptance, Australian Application No. 2016247158, Jun. 15, 2018. [cited by applicant]
Buchan et al., “Clinical Evaluation of a Real-Time PCR Assay for Identification of [cited by applicant]
Cunningham et al., “Three-Hour Molecular Detection of [cited by applicant]
Day et al., “Development of a Cell Culture Method to Isolate and Enrich [cited by applicant]
De Boer et al., “Improved Detection of Five Major Gastrointestinal Pathogens by Use of a Molecular Screening I Approach,” J. Clin. Microbiol., 48(11): 4140-4146 (2010). [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC, European Patent Application No. 13814322.7, Dec. 8, 2015. [cited by applicant]
EPO Communication under Rule 71 (3) EPC, European Patent Application No. 13814322.7, Jul. 14, 2016. [cited by applicant]
EPO Extended European Search Report, European Patent Application No. 16167200.1, Oct. 27, 2016. [cited by applicant]
EPO Extended European Search Report, European Patent Application No. 16175384.3, Sep. 20, 2016. [cited by applicant]
EPO, Communication pursuant to Article 94(3) EPC, European Application No. 16175384.3, Dec. 12, 2018. [cited by applicant]
EPO, Extended European Search Report, European Application No. 18155818.0, Jun. 26, 2018. [cited by applicant]
EPO, Partial European Search Report. European Application No. 18155818.0, Mar. 19, 2018. [cited by applicant]
Jensen et al., “Development of real-lime PCR and hybridization methods for detection and identification of hermophilic [cited by applicant]
Jin et al., “Multiplexed Bead-Based Mesofluidic System for Detection of Food-Borne Pathogenic Bacteria,” Appl. Environ. Microbiol., 75(21): 6647-6654 (2009). [cited by applicant]
Jiu et al., “Simultaneous Detection of Six Diarrhea-Causing Bacterial Pathogens with an In-House PCR-Luminex Assay,” J. Clin. Microbiol., 50(1): 98-103 (2012). [cited by applicant]
Konkel, et al. “Identification of the enteropathogens Campylobacter jejuni and Campylobacter coli based on the cadF virulence gene and its product.” J. Clin. Microbial., vol. 37(3): 510-517 (1999). [cited by applicant]
O'Leary et al., “Comparison of the EnlericBio Multiplex PCR System with Routine Culture for Detection of Bacterial Enleric Pathogens,” J. Clin. Microbiol., 47(11): 3449-3453 (2009). [cited by applicant]
PCT International Preliminary Report on Palenlability and Written Opinion, International Application No. PCT/US2013/073710, Jun. 9, 2015. [cited by applicant]
PCT Search Report, International Application No. PCT/US2013/073710, May 2, 2014. [cited by applicant]
Qin et al. “Identification of a novel genomic island conferring resistance to multiple aminoglycoside antibiotics in Campylobacter coli.” Antimicrobial Agents and Chemotherapy, 56(10): 5332-5339 (2012). [cited by applicant]
Wiemer et al. “Real-time multiplex PCr for simultaneous detection of [cited by applicant]
Wiemer et al., “Real-lime multiplex PCR for simultaneous detection of [cited by applicant]